PTAB dismisses Native American tribe information request

The Patent Trial and Appeal Board (PTAB) has denied an information request by a Native American tribe, deeming it improper for a number of reasons.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Native American tribe not entitled to sovereign immunity: PTAB

26 February 2018 The Patent Trial and Appeal Board rejected the Saint Regis Mohawk Tribe’s attempt to dismiss inter partes reviews related to dry-eye treatment Restasis late last week.

Big Pharma

Allergan tries to escape Restasis IPRs

10 January 2018 Allergan is attempting to remove itself from a series of inter partes reviews focused on dry eye treatment Restasis (cyclosporine ophthalmic emulsion).

Americas

Native American tribe seeks information on PTAB judges

4 January 2018 A Native American tribe that has signed a patent deal with Allergan has requested information on the Patent Trial and Appeal Board judges overseeing inter partes reviews involving the tribe.

More on this story

Americas

Native American tribe not entitled to sovereign immunity: PTAB

26 February 2018 The Patent Trial and Appeal Board rejected the Saint Regis Mohawk Tribe’s attempt to dismiss inter partes reviews related to dry-eye treatment Restasis late last week.

Big Pharma

Allergan tries to escape Restasis IPRs

10 January 2018 Allergan is attempting to remove itself from a series of inter partes reviews focused on dry eye treatment Restasis (cyclosporine ophthalmic emulsion).

Americas

Native American tribe seeks information on PTAB judges

More on this story

Americas

Native American tribe not entitled to sovereign immunity: PTAB

26 February 2018 The Patent Trial and Appeal Board rejected the Saint Regis Mohawk Tribe’s attempt to dismiss inter partes reviews related to dry-eye treatment Restasis late last week.

Big Pharma

Allergan tries to escape Restasis IPRs

10 January 2018 Allergan is attempting to remove itself from a series of inter partes reviews focused on dry eye treatment Restasis (cyclosporine ophthalmic emulsion).

Americas

Native American tribe seeks information on PTAB judges